Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 38.5
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Weak growth
Data is available to registered users only
Data is available to registered users only
About
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus,...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA, trading at ne
Data is available to registered users only
Buy
Sell